Business Context and Reporting Period
This Form 8-K was filed by Tocagen Inc. on April 18, 2018. The filing reports the entry into a Material Definitive Agreement with Beijing Apollo Venus Biomedical Technology Limited and ApolloBio Corp. (collectively, "ApolloBio"). The agreement grants ApolloBio an exclusive license to develop and commercialize Tocagen's Toca 511 and Toca FC products within the greater China region (including mainland China, Hong Kong, Macao, and Taiwan).
Key Financial Metrics and Agreement Terms
- Upfront Payment: ApolloBio is obligated to make an upfront payment of $16.0 million to Tocagen as a condition for the license effectiveness.
- Payment Schedule: An initial installment is due within 10 days of execution; the remainder is due within 90 days, subject to PRC currency conversion approval.
- Milestone Payments: Tocagen is eligible for up to $111.0 million in future payments upon meeting development and commercial milestones. This includes $4.0 million in near-term development milestones (e.g., completion of enrollment in the Toca 5 study).
- Royalties: Tocagen is entitled to low double-digit tiered royalty payments based on annual net sales in the Licensed Territory, subject to specified reductions.
- Cost Responsibility: ApolloBio is responsible for all development and commercialization costs within the Licensed Territory.
- Term: The agreement expires upon the expiration of the last-to-expire royalty term, which is the latest of 10 years after first commercial sale, expiration of regulatory exclusivity, or expiration of the last valid patent claim in a specific region.
Note: This filing does not provide Tocagen's consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. Those figures are typically found in periodic reports (10-K/10-Q).
Material Changes and Conditions
The primary material change is the execution of the license agreement, which is expected to become effective in the second quarter of 2018. The agreement is contingent upon:
- Registration with People's Republic of China (PRC) authorities.
- Obtaining currency conversion approval from PRC authorities for payments (except the initial installment).
- Timely payment of the upfront installments; failure to pay the initial installment within 10 days or the remainder within 90 days grants Tocagen the right to terminate.
Outlook, Risks, and Contingencies
Management highlights several risks and uncertainties regarding the forward-looking statements in this report:
- Regulatory and Currency Approvals: Uncertainty regarding the timing and success of obtaining PRC currency exchange approvals and other regulatory clearances required for payments and product importation.
- Counterparty Execution: Risks related to ApolloBio's ability to execute its strategy, secure sufficient capital, and meet diligence obligations.
- Taxation: Potential PRC withholding tax and value-added tax deductions from payments, and the uncertainty of Tocagen's ability to recover withheld amounts.
- Trade Restrictions: Potential tariffs or restrictions imposed by PRC authorities on pharmaceutical products manufactured outside the greater China region.
- Development Success: The timing and success of clinical trials and FDA approval for Toca 511 and Toca FC.
Investor Verification Checklist
- Verify the receipt of the initial $16.0 million upfront payment installment within 10 days of the April 18, 2018 execution date.
- Monitor the status of PRC currency conversion approvals required for the remainder of the upfront payment and future milestone payments.
- Confirm the registration of the agreement with PRC authorities.
- Review the full text of the License Agreement (to be filed as an exhibit to the June 30, 2018 Form 10-Q) for confidential terms and specific milestone definitions.
- Assess ApolloBio's financial health and capital resources to ensure they can fund development costs and meet payment obligations.